SCHEMBL3574151

SCHEMBL3574151

Cn1ccc2cc(NC(=O)c3cc4ccccc4n3Cc3cccc(C(F)(F)F)c3)ccc21

nearest known ligand 0.64

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PPARG P37231 18/20 0.64
ECE1 P42892 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4656155 0.94 PPARG (0.56) PPARGECE1
SCHEMBL4655349 0.92 PPARG (0.54) PPARGECE1
SCHEMBL4655334 0.92 PPARG (0.61) PPARGECE1
SCHEMBL4655243 0.92 PPARG (0.56) PPARGECE1
SCHEMBL4656134 0.90 ECE1 (0.52) PPARGECE1
SCHEMBL3578189 0.90 PPARG (0.55) PPARGECE1
SCHEMBL4656151 0.89 PPARG (0.49) PPARGECE1
SCHEMBL4656135 0.88 PPARG (0.53) PPARG
SCHEMBL4655386 0.88 ECE1 (0.51) PPARGECE1
SCHEMBL4655400 0.87 PPARG (0.49) PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101010297-B N- (1H-indolyl) -1H-indole-2-carboxamide derivatives, their preparation and their pharmaceutical use SANOFI AVENTIS 2011-07-27 CN claimed
EP-1776340-B1 N-(1H-INDOLYL)-H-INDOLE-2-CARB0XAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI AVENTIS (FR) 2008-12-03 EP claimed
CN-101010297-B N- (1H-indolyl) -1H-indole-2-carboxamide derivatives, their preparation and their pharmaceutical use SANOFI AVENTIS 2011-07-27 CN disclosed
US-7781477-B2 Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives SANOFI-AVENTIS (FR) 2010-08-24 US disclosed
US-20090286846-A1 Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives SANOFI-AVENTIS (FR) 2009-11-19 US disclosed
US-7582671-B2 Therapeutic use of N-(1H-indolyl)-1H-indole-2-carboxamide derivatives SANOFI-AVENTIS (FR) 2009-09-01 US disclosed
EP-1776340-B1 N-(1H-INDOLYL)-H-INDOLE-2-CARB0XAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI AVENTIS (FR) 2008-12-03 EP disclosed
US-20080227843-A1 THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES SANOFI-AVENTIS (FR) 2008-09-18 US disclosed
US-7384969-B2 N-(1H-indolyl)-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2008-06-10 US disclosed
CN-101010297-A N- (1H-indolyl) -1H-indole-2-carboxamide derivatives, their preparation and their pharmaceutical use SANOFI AVENTIS (FR) 2007-08-01 CN disclosed
US-20070149602-A1 N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149602-A1 N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE IDO1, IDO2, NPY5R PPARG 2147/4885ECE1 1424/4885
US-20080227843-A1 THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES NPY5R, TPH2, TPH1 PPARG 1964/4885ECE1 1609/4885
US-20090286846-A1 Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives NPY5R, TPH2, TPH1 PPARG 1964/4885ECE1 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.